How does CSJ's PE Ratio compare to its peers?

CSJ is good value based on its Price-To-Earnings Ratio (37.1x) compared to the peer average (53.1x).

How does CSJ's PE Ratio compare vs other companies in the European Biotechs Industry?

CSJ is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the European Biotechs industry average (24.1x).

What is CSJ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CSJ's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of CSJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CSJ (CHF180.92) is trading below our estimate of [[fair value]] (CHF236.67)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

CSL (BRSE:CSJ) - Stock Price, News & Analysis

CSJ Stock Overview

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details

CSJ fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	5/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 23.6% below our estimate of its fair value

Earnings are forecast to grow 13.11% per year

Earnings grew by 20.4% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

CSL Limited Competitors

Lonza Group

SWX:LONN

CHF 37.3b

Novartis

SWX:NOVN

CHF 185.4b

Roche Holding

SWX:ROG

CHF 202.8b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$81.0b

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share Price	AU$180.92
52 Week High	AU$0
52 Week Low	AU$0
Beta	0.33
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-13.00%
5 Year Change	n/a
Change since IPO	-9.73%

Recent updates

Shareholder Returns

	CSJ	CH Biotechs	CH Market
7D	0%	-2.8%	1.0%
1Y	n/a	98.7%	6.0%

Return vs Industry: Insufficient data to determine how CSJ performed against the Swiss Biotechs industry.

Return vs Market: Insufficient data to determine how CSJ performed against the Swiss Market.

Price Volatility

Is CSJ's price volatile compared to industry and market?
CSJ volatility
CSJ Average Weekly Movement	n/a
Biotechs Industry Average Movement	12.7%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.8%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: CSJ's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine CSJ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSJ fundamental statistics
Market cap	CHF 84.02b
Earnings (TTM)	CHF 2.28b
Revenue (TTM)	CHF 12.78b

37.1x

P/E Ratio

6.6x

P/S Ratio

Is CSJ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSJ income statement (TTM)
Revenue	US$14.80b
Cost of Revenue	US$7.10b
Gross Profit	US$7.71b
Other Expenses	US$5.06b
Earnings	US$2.64b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 10, 2025

Earnings per share (EPS)	5.46
Gross Margin	52.06%
Net Profit Margin	17.85%
Debt/Equity Ratio	54.2%

How did CSJ perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

48%

Payout Ratio

CSJ Stock Overview

Rewards

Risk Analysis

CSL Limited Competitors

SWX:LONN

CHF 37.3b

SWX:NOVN

CHF 185.4b

SWX:ROG

CHF 202.8b

NasdaqGS:REGN

US$81.0b

Price History & Performance

Recent News & Updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

New minor risk - Financial position

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

High number of new directors

CSL Limited Provides Financial Guidance for Fiscal 2022